SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-056943
Filing Date
2021-02-25
Accepted
2021-02-25 16:06:19
Documents
14
Period of Report
2021-02-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d48184d8k.htm   iXBRL 8-K 26741
2 EX-99.1 d48184dex991.htm EX-99.1 49708
6 GRAPHIC g48184g0225102607566.jpg GRAPHIC 4044
  Complete submission text file 0001193125-21-056943.txt   218598

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ziop-20210225.xsd EX-101.SCH 3091
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ziop-20210225_lab.xml EX-101.LAB 18908
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ziop-20210225_pre.xml EX-101.PRE 11877
7 EXTRACTED XBRL INSTANCE DOCUMENT d48184d8k_htm.xml XML 3539
Mailing Address ONE FIRST AVENUE PARRIS BUILDING 34, NAVY YARD PLAZA BOSTON MA 02129
Business Address ONE FIRST AVENUE PARRIS BUILDING 34, NAVY YARD PLAZA BOSTON MA 02129 617-259-1970
ZIOPHARM ONCOLOGY INC (Filer) CIK: 0001107421 (see all company filings)

IRS No.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 21680259
SIC: 2834 Pharmaceutical Preparations